• 1
    American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 71322.
  • 2
    Holbrook AM, for Ontario Musculoskeletal Therapy Review Panel. Ontario treatment guidelines for osteoarthritis, rheumatoid arthritis and acute musculoskeletal injury. Toronto: Queen's Printer of Ontario; 2000.
  • 3
    Lipsky PE. Algorithms for the diagnosis and management of musculoskeletal complaints: introduction. Am J Med 1997; 103: 1S2S.
  • 4
    Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology 2000; 39: 2833.
  • 5
    Clarke AE, Zowall H, Levinton C, Assimakopoulos H, Sibley JT, Haga M, et al. Direct and indirect medical costs incurred by Canadian patients with rheumatoid arthritis: a 12 year study. J Rheumatol 1997; 24: 105160.
  • 6
    Anis AH, Tugwell PX, Wells GA, Stewart DG. A cost effectiveness analysis of cyclosporine in rheumatoid arthritis. J Rheumatol 1996; 23: 60916.
  • 7
    Kavanaugh A, Heudebert G, Cush J, Jain R. Cost evaluation of novel therapeutics in rheumatoid arthritis (CENTRA): a decision analysis model. Semin Arthritis Rheum 1996; 25: 297307.
  • 8
    Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S, for the COBRA Trial Group (Combinatietherapie Bij Reumatoide Artritis). Cost-effectiveness and cost-utility of combination therapy in early rheumatoid arthritis: randomized comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone. Br J Rheumatol 1998; 37: 11029.
  • 9
    Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000; 43: 231627.
  • 10
    Albert DA, Aksentijevich S, Hurst S, Fries JF, Wolfe F. Modeling therapeutic strategies in rheumatoid arthritis: use of decision analysis and Markov models. J Rheumatol 2000; 27: 64452.
  • 11
    Kobelt G, Eberhardt K, Jönsson L, Jönsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999; 42: 34756.
  • 12
    Maetzel A, Bombardier C, Strand V, Tugwell P, Wells G. How US and Canadian rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998; 25: 23318.
  • 13
    Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying antirheumatic drugs. Rheumatology (Oxford) 2000; 39: 97581.
  • 14
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.
  • 15
    Paulus HE, Egger MJ, Ward JR, Williams HJ Cooperative Systematic Studies of Rheumatic Diseases Group. Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 1990; 33: 47784.
  • 16
    Van Gestel AM, Prevoo MLL, van 't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 3440.
  • 17
    Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159: 254250.
  • 18
    Ontario Ministry of Health. Schedule of benefits: physician services under the Health Insurance Act. Toronto: Ontario Ministry of Health; 1998.
  • 19
    Ontario Hospital Association, Ontario Ministry of Health. Ontario case costing project: Ontario guide to case costing. Version 1.1. Toronto: Ontario Hospital Association; 1995.
  • 20
    Canadian Socio-Economic Information Management System II. Ratios of real consumption (medical and health care) per person in the United States compared with Canada for selected components of the gross domestic product. United Nations International Comparison Project Classification (consumption-based). Ottawa: Statistics Canada. CANSIM II SERIES V647911; 2002.
  • 21
    O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996; 334: 128791.
  • 22
    Möttönen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al, and the FIN-RACo trial group. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999; 353: 156873.